Biosuccess Biotech Co. Ltd. ,
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 1
Terminated
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Biosuccess Biotech Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT01795924
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸City of Hope, Duarte, California, United States
© Copyright 2025. All Rights Reserved by MedPath